- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Crinetics Pharmaceuticals Inc (CRNX)
Assess today's live Crinetics Pharmaceuticals Inc (CRNX) share price, performance and insights using our live NASDAQ: CRNX stock exchange data.
Analyse the historical data and Crinetics Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Crinetics Pharma share price buy/sell indicators using real-time data (or discuss the Crinetics Pharma (CRNX) stock price today with other investors in the Crinetics Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ CRNX share price (ISIN: US22663K1079) to enhance your trading decisions with our free investment tools and resources.
What Is the Crinetics Pharmaceuticals Inc Share Price Today?
The Crinetics Pharma share price today is 48.87.
What Is the Stock Symbol for Crinetics Pharmaceuticals Inc
The stock symbol (or 'ticker') for Crinetics Pharmaceuticals Inc is "CRNX."
What Stock Exchange Does Crinetics Pharmaceuticals Inc Trade On?
Crinetics Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Crinetics Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Crinetics Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Crinetics Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Crinetics Pharma share price buy/sell indicators using real-time data (or discuss the Crinetics Pharma (CRNX) stock price today with other investors in the Crinetics Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ CRNX share price (ISIN: US22663K1079) to enhance your trading decisions with our free investment tools and resources.
What Is the Crinetics Pharmaceuticals Inc Share Price Today?
The Crinetics Pharma share price today is 48.87.
What Is the Stock Symbol for Crinetics Pharmaceuticals Inc
The stock symbol (or 'ticker') for Crinetics Pharmaceuticals Inc is "CRNX."
What Stock Exchange Does Crinetics Pharmaceuticals Inc Trade On?
Crinetics Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Crinetics Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Crinetics Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
48.61
49.40
52 wk Range
24.10
54.18
CRNX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
48.6149.40
52 wk Range
24.1054.18
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CRNX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
80.21
Upside
+64.14%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Crinetics Pharma Company Profile
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing’s disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves’ disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Crinetics Pharmaceuticals Inc SWOT Analysis
Promising Pipeline | Crinetics' lead candidates paltusotine and atumelnant show potential to revolutionize treatments for acromegaly and congenital adrenal hyperplasia |
Market Expansion | Explore how Crinetics' oral therapies could tap into large untreated patient populations, potentially expanding the acromegaly market beyond current estimates |
Analyst Projections | Delve into analysts' expectations, with price targets ranging from $90 to $97 and projected 2026 revenue of $45 million for paltusotine in acromegaly |
Growth Potential | Learn about Crinetics' multi-indication strategy and its potential to disrupt multiple endocrine disorder markets, with estimated peak sales exceeding $5 billion annually |
Crinetics Pharmaceuticals Inc Earnings Call Summary for Q3/2025
- Crinetics Pharmaceuticals missed Q3 2025 forecasts with EPS of -1.38 (vs -1.25 expected) and revenue of $143,000 (vs $491,000 expected), yet stock rose 2.26% in after-hours trading.
- R&D expenses increased to $90.5 million from $80.3 million in Q2, while SG&A expenses rose to $52.3 million from $49.8 million, contributing to the earnings shortfall.
- The company maintains strong financial stability with $1.1 billion in cash reserves, expected to fund operations into 2029, despite guidance of $340-$370 million net cash use for 2025.
- CEO Dr. Scott Struthers emphasized the strategic goal of making Palsanafy the 'first-line treatment of choice for acromegaly,' with full launch metrics expected in Q1 2026.
- Early positive feedback from physicians and patients on Palsanafy launch, along with promising payer approvals, suggests potential for future revenue growth despite current shortfalls.
Last Updated: 06/11/2025, 23:18
Read Full TranscriptCompare CRNX to Peers and Sector
Metrics to compare | CRNX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRNXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.0x | −7.5x | −0.6x | |
PEG Ratio | 0.50 | −1.19 | 0.00 | |
Price/Book | 4.3x | 1.6x | 2.6x | |
Price / LTM Sales | 3,021.1x | 2.4x | 3.2x | |
Upside (Analyst Target) | 69.8% | 75.8% | 41.8% | |
Fair Value Upside | Unlock | 30.6% | 5.1% | Unlock |
Analyst Ratings
14 Buy
2 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 80.21
(+64.14% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
-1.38 / -1.25
Revenue / Forecast
143.00K / 491.00K
People Also Watch
FAQ
What Is the Crinetics Pharma (CRNX) Share Price Today?
The live Crinetics Pharma share price today is 48.87
What Stock Exchange Does Crinetics Pharma (CRNX) Trade On?
Crinetics Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Crinetics Pharma?
The stock symbol (also called a 'ticker') for Crinetics Pharma is "CRNX."
What Is the Current Crinetics Pharma Market Cap?
As of today, Crinetics Pharma market capitalisation is 4.64B.
What Is Crinetics Pharma's (CRNX) Earnings Per Share (TTM)?
The Crinetics Pharma EPS is currently -4.54 (Trailing Twelve Months).
When Is the Next Crinetics Pharma Earnings Date?
Crinetics Pharma's next earnings report will be released on 04 Mar 2026.
Is CRNX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Crinetics Pharma moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Crinetics Pharma Stock Split?
Crinetics Pharma has split 0 times. (See the CRNX stock split history page for full effective split date and price information.)
How Many Employees Does Crinetics Pharma Have?
Crinetics Pharma has 437 employees.
What is the current trading status of Crinetics Pharma (CRNX)?
As of 24 Dec 2025, Crinetics Pharma (CRNX) is trading at a price of 48.87, with a previous close of 48.87. The stock has fluctuated within a day range of 48.61 to 49.40, while its 52-week range spans from 24.10 to 54.18.
What Is Crinetics Pharma (CRNX) Price Target According to Analysts?
The average 12-month price target for Crinetics Pharma is USD80.21429, with a high estimate of USD108 and a low estimate of USD45. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +64.14% Upside potential.
What Is the CRNX After Hours Price?
CRNX's last after hours stock price is 49.73, the stock has decreased by 0.86, or 1.76%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.